Risk of contralateral breast cancer and ovarian cancer in BRCA1 founder mutation (5382insC or 4154delA) carriers with primary breast cancer

The objective of this study is to estimate the risk of new cancer events, (metachronous contralateral breast cancer (CBC) and ovarian cancer (OC)) in BRCA1 mutation carriers with primary breast cancer in population of Latvia, dominated by two founder mutation types. Secondary goal is to verify the risk reduction associated with contralateral prophylactic mastectomy (CPM) and bilateral prophylactic salpingo-ophorectomy (BPSO) procedures.

Source: European Journal of Cancer - September 30, 2020 Category: Cancer & Oncology Authors: P. Loza, A. Irmejs, J. Maksimenko, G. Trofimovics, J. Gardovskis, E. Miklasevics, Z. Daneberga Tags: POSTERS A: Local Regional Treatment – Surgery Source Type: research